HL7 Antitrust Policy

Professional Associations, such as HL7, which bring together competing entities are subject to strict scrutiny under applicable antitrust laws. HL7 recognizes that the antitrust laws were enacted to promote fairness in competition and, as such, supports laws against monopoly and restraints of trade and their enforcement. Each individual participating in HL7 meetings and conferences, regardless of venue, is responsible for knowing the contents of and adhering to the HL7 Antitrust Policy as stated in §05.01 of the Governance and Operations Manual (GOM).

Attendees

Agenda Items and Notes

Meeting Notes from previous meeting

• 2021-11-22 Agenda/Meeting Notes - approved by general consent

Project Review

Project Proposals

• Project Proposals in Review - none to review

Project Scope Statements

• Project Scope Statements - none to review

Discussion of MedicationKnowledge changes (Jean Duteau)

• 29 Nov 2021 - no discussion

Catalog Updates (John Hatem)

• 29 Nov 2021 - no meeting last week; next meeting Dec 3, 2021

Workflow Update (John Hatem) 

• 29 Nov 2021 - no meeting today, next meeting Dec 6, 2021

Healthcare Product Update (John Hatem)

• 29 Nov 2021
  • discussed device Jira's - no pharmacy impact
  • Insulin and IVIG are not Biologically Derived Products

NCPDP Updates (NCPDP Members)

• 29 Nov 2021 

Global Supply Chain Project (Scott)

• 29 Nov 2021 

Medication List Guidance project (John)

• 22 Nov 2021 - no updates this week

Projects

Pharmacy Templates

• waiting for requirements from Christof and then will decide on next steps for new version
• Still waiting for approval of change request in Europe
  • additional elements to be added - part relationship

PDex Formulary (Corey)

• Approval of IG for ballot - vote November 29
  • https://build.fhir.org/ig/HL7/davinci-pdex-formulary/
  • Motion to approve this IG for January 2022 ballot - Corey/John - 12-0-1
• Bulk Data change - not specifically included in the scope of the PSS - but PSS is not specific to formulary
  • Need to look at the scope of the PSS to be clear about what the PSS is about

Medication List Project from EHR 

• 29 Nov 2021 

Nutrition

FHIR (Group)

BR&R managed resources review

• no recent meetings

New Resource - FormularyItem

• January 21 - new resource proposal deadline for May 2022 ballot

Preparation for Normative

• Melva to work with John about QA needed

Trackers - link to pharmacy unresolved Jira trackers (see trackers for details / resolutions)

Any Other Business

• Nutrition
  • November 17, 2021 Care Plan Topics Notes
    • move to call on December 6, 2021
• International Patient Access
  • In progress IG, for ballot in Jan: HL7.FHIR.UV.IPA\International Patient Access - FHIR v4.0.1
  • PSS: [PSS-1808] International Patient Access - Jira (hl7.org)
  • Med profiles:
    • HL7.FHIR.UV.IPA\IPA-MedicationRequest - FHIR v4.0.1
    • HL7.FHIR.UV.IPA\IPA-MedicationStatement - FHIR v4.0.1
    • HL7.FHIR.UV.IPA\IPA-Medication - FHIR v4.0.1
  • Next call with Patient Care - Wednesday, Dec 1st at 10am Eastern - John will try to attend
• RTPBC FHIR IG - Frank
  • The RTPBC FHIR IG states that it intends to be compatible with the NCPDP Real Time Prescription Benefit (RTPB) standard--which is used in provider-to-payer exchanges--so that patients and their providers receive consistent information.
  • With the aim of helping keep the two standards in sync, the NCPDP Consumer RTPB task group recently performed a review of new content added to the NCPDP provider RTPB standard. The group identified some data element and guidance additions made to the NCPDP standard that it would like to suggest be considered for the HL7 RTPBC FHIR IG.
  • The NCPDP group is wondering what would be the best process for bringing these suggestions forward. For example, putting in tracker items and then reviewing in Pharmacy? Or bringing to CARIN first?
  • Proposed adding issues to Jira and then review to determine how to do an update

Next meeting

• December 6, 2021